Back to News
Market Impact: 0.1
AbbVie, Brise Expand Migraine Drug Partnership
Source: Nasdaq
Healthcare & BiotechM&A & Restructuring
Brise Pharmaceuticals provided an update on its exclusive license agreement with AbbVie, entered into in 2024. The article excerpt gives no details about the update or its financial implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.00
More News
- Wells Fargo raises Abbvie stock price target to $340 on pipeline
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- Marvell, Lumentum tout historic $115B deal to create ‘category leader' in AI connectivity
- Kimberly-Clark closes its acquisition of Tylenol maker Kenvue. What to expect next
- In one of the largest deals in tech history, Marvell buys Lumentum for $115B
- Donaldson at 50th annual automotive symposium: growth, margins and Facet